ro7198457
Vaccineexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 21, 2017 (NCT03289962)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04486378 | Phase 2 | Nov 30, 2020 | Biontech |
| NCT04267237 | Phase 2 | Aug 17, 2020 | Roche |
| NCT04161755 | Phase 1 | Nov 11, 2019 | Genentech, Memorial Sloan-Kettering Cancer Center |
| NCT03815058 | Phase 2 | Jan 8, 2019 | Biontech, Genentech, Roche |
| NCT03289962 | Phase 1 | Dec 21, 2017 | Biontech, Genentech, Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biontech | For profit | 3 | 1 | 2 | 2017 |
| Genentech | For profit | 3 | 2 | 2 | 2017 |
| Roche | For profit | 3 | 1 | 2 | 2017 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1